TB-500
- Category
- Tissue Repair & Recovery
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic fragment of thymosin beta-4, marketed for tendon, muscle, and ligament recovery. The fragment's evidence is limited to preclinical work; human safety and efficacy have not been established. The cited dry-eye trial concerns full-length thymosin beta-4. Because thymosin beta-4 drives new blood-vessel growth, a theoretical tumor concern is unresolved. Not FDA-approved, restricted by the FDA over safety, and mostly sold as unregulated products online.
Read Full recordStudied uses & evidence
Studied uses(7)
Wound healing
MediumThe 42–61% result came from rat wounds treated with full-length thymosin beta-4. Its human ulcer trials do not establish TB-500 fragment efficacy.
Cardiac repair
LowFull-length thymosin beta-4 has preclinical cardiac findings. The cited RGN-352 record does not establish human scar reduction, and no TB-500 fragment cardiac trial was identified.
Corneal healing
MediumA small full-length thymosin beta-4 eye-drop trial showed a nonsignificant four-week healing trend; it did not test TB-500.
Evidence limits
- Evidence Level
- Preclinical
TB-500 fragment has no established human safety or efficacy evidence. The cited Phase I–III programs concern full-length thymosin beta-4, including RGN-259 eye drops, and cannot establish benefits or safety for injected TB-500.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighTB-500 promotes cell migration and angiogenesis, which may accelerate tumor growth or metastasis.
Recent head injury with active bleeding
ModerateAngiogenic properties may complicate recovery from hemorrhagic injuries.
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Not FDA-approved for any indication
HighFDA's drug reviewers found safety concerns and recommended against listing it; compounding is limited to the conditions of a draft interim HHS policy
HighPromotes angiogenesis; theoretical concern for tumor vascularization
TheoreticalLimited long-term human safety data
ModerateFull-length thymosin beta-4's ARISE-3 dry-eye trial missed its co-primary endpoints; this was not a TB-500 fragment trial
ModerateUnregulated products sold online
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.